Medicare Enrolled
Dr. Shanmuga Pudunagar Subbiah, MD
Medical Oncology · Upland, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pudunagar Subbiah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pudunagar Subbiah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pudunagar Subbiah
Dr. Shanmuga Pudunagar Subbiah is a medical oncology specialist in Upland, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Pudunagar Subbiah performed 34,939 Medicare services across 1,467 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pudunagar Subbiah received a total of $89,187 from 40 pharmaceutical and/or device companies across 301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pudunagar Subbiah is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 12% volume in CA
$89,187 industry payments
Medicare Practice Summary
Medicare Utilization ↗34,939
Medicare services
Top 12% in CA for medical oncology
1,467
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,941 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
18,000 | $1 | $4 |
| Anti-nausea injection (aprepitant) | 6,240 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 3,420 | $18 | $82 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
2,046 | $66 | $246 |
| Anti-nausea injection (ondansetron/Zofran) | 1,564 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,306 | $0 | $0 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
551 | $65 | $336 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
377 | $101 | $468 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
267 | $14 | $93 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
225 | $145 | $605 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
166 | $119 | $606 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
110 | $12 | $81 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
90 | $59 | $295 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
73 | $26 | $147 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
72 | $2 | $20 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
65 | $25 | $109 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
51 | $152 | $665 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 51 | $134 | $621 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
49 | $56 | $269 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
47 | $25 | $134 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
45 | $1 | $4 |
| New patient office visit, complex (60-74 min) | 44 | $164 | $811 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
32 | $23 | $103 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
21 | $31 | $134 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
15 | $100 | $384 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $106 | $328 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
52.6% high complexity
37.3% medium
10.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$89,187
Total received (2018-2024)
Avg $12,741/year across 7 years
Top 15% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
301
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$53,291 (59.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$31,180 (35.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,237 (3.6%)
Other
Charitable contributions, space rental, and other categories
$1,479 (1.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$10,171
2023
$5,311
2022
$15,179
2021
$3,561
2020
$17,229
2019
$22,744
2018
$14,993
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$6,749
Novartis Pharmaceuticals Corporation
$1,479
BeiGene USA, Inc.
$675
SOBI, INC
$230
Merck Sharp & Dohme LLC
$163
Janssen Biotech, Inc.
$129
Astellas Pharma US Inc
$103
EMD Serono, Inc.
$86
Aveo Pharmaceuticals, Inc.
$70
Gilead Sciences, Inc.
$59
Lilly USA, LLC
$52
Karyopharm Therapeutics Inc.
$49
Regeneron Healthcare Solutions, Inc.
$39
Amgen Inc.
$32
Daiichi Sankyo Inc.
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
Celgene Corporation
$28
ImmunoGen, Inc.
$26
ABBVIE INC.
$25
PFIZER INC.
$23
Janssen Pharmaceuticals, Inc
$22
Bayer Healthcare Pharmaceuticals Inc.
$22
Eisai Inc.
$21
GENZYME CORPORATION
$18
E.R. Squibb & Sons, L.L.C.
$15
Top 3 companies account for 87.5% of 2024 payments
All-time payments by company (2018-2024) ›
Alexion Pharmaceuticals, Inc.
$41,848
AstraZeneca Pharmaceuticals LP
$11,724
Exelixis Inc.
$9,304
Novartis Pharmaceuticals Corporation
$7,212
PFIZER INC.
$4,056
Incyte Corporation
$3,465
Daiichi Sankyo Inc.
$2,740
E.R. Squibb & Sons, L.L.C.
$2,033
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,655
Celgene Corporation
$1,655
BeiGene USA, Inc.
$675
Amgen Inc.
$426
Astellas Pharma US Inc
$342
Novocure GmbH
$250
SOBI, INC
$230
Gilead Sciences, Inc.
$183
Merck Sharp & Dohme LLC
$182
Janssen Biotech, Inc.
$167
Merck Sharp & Dohme Corporation
$109
Genentech USA, Inc.
$106
Bayer HealthCare Pharmaceuticals Inc.
$91
EMD Serono, Inc.
$86
Karyopharm Therapeutics Inc.
$81
Lilly USA, LLC
$77
Aveo Pharmaceuticals, Inc.
$70
Bayer Healthcare Pharmaceuticals Inc.
$55
Epizyme, Inc.,
$46
Regeneron Healthcare Solutions, Inc.
$39
GENZYME CORPORATION
$38
Takeda Pharmaceuticals U.S.A., Inc.
$29
ImmunoGen, Inc.
$26
ABBVIE INC.
$25
Seagen Inc.
$24
Heron Therapeutics, Inc.
$23
Myriad Genetic Laboratories, Inc.
$22
Janssen Pharmaceuticals, Inc
$22
Eisai Inc.
$21
GlaxoSmithKline, LLC.
$20
Pharmacyclics LLC, an AbbVie Company
$18
Foundation Medicine, Inc.
$14
Top 3 companies account for 70.5% of all-time payments
Associated products mentioned in payments ›
Alecensa · BAVENCIO · BOSULIF · BRUKINSA · Blincyto · CALQUENCE · CARVYKTI · CINVANTI · Cabometyx · DARZALEX · ELAHERE · ELITEK · EMPLICITI · ENHERTU · Enhertu · FOTIVDA · FOUNDATIONONE · Fabhalta · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYCHOICE CDX · Nplate · Nubeqa · OJJAARA · OPDIVO · PIQRAY · PROMACTA · Perjeta · Pomalyst · Revlimid · SANDOSTATIN · SARCLISA · SCEMBLIX · SOLIRIS · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TUKYSA · Trodelvy · Truqap · ULTOMIRIS · Ultomiris · VERZENIO · VONJO · Venclexta · Vitrakvi · XGEVA · XPOVIO · XTANDI · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (60%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Medical oncologists within 10 mi
43
Per 100K population
2.0
County median income
$82,184
Nearest hospital
SAN ANTONIO REGIONAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pudunagar Subbiah is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with speaking/promotional industry engagement in the top 15% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pudunagar Subbiah experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Pudunagar Subbiah performed 18,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pudunagar Subbiah receive payments from pharmaceutical companies?
Yes. Dr. Pudunagar Subbiah received a total of $89,187 from 40 companies across 301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pudunagar Subbiah's costs compare to other medical oncologists in Upland?
Dr. Pudunagar Subbiah's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pudunagar Subbiah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Upland
Browse medical oncologists in Upland ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Alexion Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Alexion Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology